Join us for an insightful lecture by Prof Maria Teresa Voso from University of Rome Tor Vergata in Italy, as she discusses the advances in the treatment of a rare subtype of AML, the acute promyelocytic leukemia (APL). As the PML::RARA rearrangement, resulting in a fusion protein that disrupts retinoic acid signaling and PML function, is the hallmark driver of APL, it is used as target for APL treatment.

Listen to Prof Voso as she talks about the scientific developments leading to significant improvements in clinical outcomes for patients with APL and the role of ATRA / ATO therapy, which combines all-trans retinoic acid (ATRA) and arsenic trioxide (ATO).

Prof Voso highlights contributions of the late prof. Francesco Lo Coco, the significance of the EU-wide HARMONY registry and other collaborative efforts in establishing the optimal treatment regimens for APL. This podcast also provides insights into remaining open issues in the clinical management of APL, including high-risk APL for which the results of the much-anticipated APOLLO trial may provide some answers. 

This is part of a series of lectures recorded at the EHA congress in Madrid in June 2024. The podcasts in this series are better consumed in video form because of the accompanying slide content. More lectures will be available in the future. Stay tuned!

For more information about a past or upcoming EHA Congress, visit https://ehaweb.org/congress/

Guest: Prof Maria Teresa Voso

What did you think of this podcast? Share your opinions with us in this short feedback survey.

Provide Feedback

Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.

https://ehaedu.org/Campus

Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.

Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/

Facebook: https://e-h-a.link/facebook

LinkedIn: https://www.linkedin.com/company/eha/

Email us: [email protected]

Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe 

Join us for this engaging debate on the future of acquired TTP (aTTP) treatment chaired by Dr. Eleni Gavriilaki from Aristotle University of Thessaloniki in Greece. This discussion features Prof. Marie Scully from University College London Hospital in UK and Prof. Paul Coppo from Saint-Antoine Hospital in Paris, France. The debate centers on whether therapeutic plasma exchange (PEX) combined with immunosuppression, long considered the standard treatment for acute aTTP episodes, has become obsolete with the advent of new therapies.  

First Prof. Scully argues that plasmapheresis is indeed a thing of the past, citing its complexity and inherent safety concerns. Prof Scully predicts that the best alternative option will incorporate the use of recombinant ADAMTS13, caplacizumab and immunosuppression primarily with steroids and anti-CD-20 therapy. 

In contrast, Prof Coppo argues that a PEX-free strategy cannot be universally applied to all aTTP patients, regardless of clinical presentation and severity because there is insufficient data yet to support this approach, the availability of caplacizumab is not guaranteed. 

Tune in for this debate to hear further our experts’ views on the impact of treatment costs on availability and clinical decision making.  

Guests:

Dr Eleni Gavriilaki 

Aristotle University of Thessaloniki, Greece 

Prof Marie Scully

University College London, UCLH, London, UK 

Prof Paul Coppo

Sorbonne University and Saint-Antoine Hospital, Paris, France 

What did you think of this podcast? Share your opinions with us in this short feedback survey.

Provide Feedback

Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.

https://ehaedu.org/Campus

Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.

Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/

Facebook: https://e-h-a.link/facebook

LinkedIn: https://www.linkedin.com/company/eha/

Email us: [email protected]

Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe 

Join us in this podcast episode to get a glimpse of what the future holds in the big field of innovation in hematology. With the help of our host, Dr Gregor Hormann (MLL Munich Leukemia Laboratory, Germany), you will be taken on a journey toward a future that is already here.   

Dr Hormann will discuss the many potentials of AI in hematology and oncology, including the automated integrated diagnostic tools, from morphology to chromosomal banding analysis in a few minutes, new classification algorithms, and innovative large language models (LLMs) assisting physicians in the diagnosis prediction.  

The take-home message? "AI will not replace physicians. However, physicians who use AI will replace those who don't." 

Host: Dr Wilson Lim

Guest: Dr Gregor Hormann

What did you think of this podcast? Share your opinions with us in this short feedback survey.

Provide Feedback

Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.

https://ehaedu.org/Campus

Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.

Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/

Facebook: https://e-h-a.link/facebook

LinkedIn: https://www.linkedin.com/company/eha/

Email us: [email protected]

Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe 

Tune in to EHA Unplugged for an engaging chat with Professor Lars Bullinger from Charité University Medicine, Berlin. He'll break down the latest in myeloid disease classification, discussing how new genetic insights are transforming our understanding of MDS and AML.

Discover the hurdles clinicians face, the promise of innovative treatments, and the future of preventive medicine, including the impact of clonal hematopoiesis and cutting-edge sequencing tech.  

Host: Prof Kirsten Grønbæk

Guest: Professor Lars Bullinger

What did you think of this podcast? Share your opinions with us in this short feedback survey.

Provide Feedback

Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.

https://ehaedu.org/Campus

Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.

Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/

Facebook: https://e-h-a.link/facebook

LinkedIn: https://www.linkedin.com/company/eha/

Email us: [email protected]

Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe 

Join us for an insightful episode featuring Prof David Rees from King’s College Hospital in London as he discusses screening practices for Sickle Cell disease (SCD). Hosted by Dr Sarah de Vlieger, this discussion explores both antenatal and neonatal screening practices for Sickle Cell disease.

The conversation begins with an examination of antenatal screening challenges, comparing various techniques such as carrier screening, amniocentesis, chorionic villus sampling, and emerging non-invasive prenatal testing. Prof Rees and Dr de Vlieger then address the complex decisions arising from these test results and the disparities in screening access across different countries and cultures.

Moving to neonatal screening, Prof Rees emphasizes its crucial role in implementing early preventive measures. He advocates for the inclusion of Sickle Cell testing in general neonatal screening programs throughout Europe and aspires for screening to become more accessible in regions with higher disease prevalence.

Host: Sarah de Vlieger, EHA Head of Education

Guest: Prof David Rees

What did you think of this podcast? Share your opinions with us in this short feedback survey.

Provide Feedback

Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.

https://ehaedu.org/Campus

Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.

Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/

Facebook: https://e-h-a.link/facebook

LinkedIn: https://www.linkedin.com/company/eha/

Email us: [email protected]

Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe 

Join us for an engaging episode with Dr. Stephen Hibbs from Queen Mary University of London as he discusses the environmental impacts of hematology. Alongside our host Dr. Sarah de Vlieger, they explore how climate change is already affecting hematology, emphasizing that these effects are being felt now rather than in the future.

The conversation highlights how climate change alters aspects of hematology practice, such as the risk of transfusion-transmitted infections due to evolving disease vectors. Dr. Hibbs describes also the surprising link between extreme heat during pregnancy and an increased risk of children developing ALL (acute lymphoblastic leukemia). He further discusses practice-changing initiatives, like using sevoflurane instead of desflurane as an anesthetic to reduce environmental impact, and explains his work on improving the logistics of blood transfusions to lessen their ecological footprint.

Finally, Dr. Hibbs encourages hematologists to focus on actionable steps to minimize their environmental impact, advocating for practical changes in clinical practices and increased awareness of the healthcare sector's contribution to global emissions.

Host: Dr Sarah de Vlieger

Guest: Dr Stephen Hibbs

What did you think of this podcast? Share your opinions with us in this short feedback survey.

Provide Feedback

Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.

https://ehaedu.org/Campus

Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.

Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/

Facebook: https://e-h-a.link/facebook

LinkedIn: https://www.linkedin.com/company/eha/

Email us: [email protected]

Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe 

Join us in this podcast episode, exploring with Prof Matteo Della Porta (Humanitas Research Hospital, Milano, Italy) the emerging role of "synthetic patients" in hematological clinical trials. Innovative generative artificial intelligence models allow today to create synthetic data set based on real patients, suitable to be used as control groups in clinical trials, helping in the identification of disease mechanisms and improving the prognostic risk prediction.

Prof Della Porta will dig into the challenges and opportunities linked to these new technologies, from the overcoming of privacy barriers to the regulatory needs required with the advent of synthetic data in clinical trial settings, opening the door for novel models in clinical research.

Host: Dr Enrica Orsini

Guest: Prof Matteo Della Porta

What did you think of this podcast? Share your opinions with us in this short feedback survey.

Provide Feedback

Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.

https://ehaedu.org/Campus

Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.

Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/

Facebook: https://e-h-a.link/facebook

LinkedIn: https://www.linkedin.com/company/eha/

Email us: [email protected]

Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe 

Join us for an insightful interview with Prof Bruno Paiva from Clinical University of Navarra in Pamplona, Spain, as he and our host Dr. Isabel Olivera-Martinez, discuss the latest technical approaches to improving monitoring, risk stratification and differential diagnosis of patients with monoclonal gammopathies including MGUS (monoclonal gammopathy of unknown significance), smoldering myeloma and multiple myeloma.  

Prof Paiva begins by highlighting the importance of developing less invasive tools to assess MRD, given that multiple myeloma patients are living longer and need to be monitored multiple times. 

He further describes the potential updates to the guidelines of the International Myeloma Working Group that may include the use of mass spectrometry, as a more sensitive method to quantify the M-component as well as the application of next-generation techniques - such as next-generation flow cytometry and next-generation sequencing- to monitor disease in peripheral blood, as a complement to bone marrow assessments.

Prof Paiva also discusses the two largest ongoing translational studies, which aim to elucidate the “unknown” and define the clinical significance of MGUS and smoldering myeloma for each individual patient. 

Host: Isabel Olivera-Martinez, PhD, Medical Writer 

Guest: Prof Bruno Paiva

What did you think of this podcast? Share your opinions with us in this short feedback survey.

Provide Feedback

Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.

https://ehaedu.org/Campus

Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.

Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/

Facebook: https://e-h-a.link/facebook

LinkedIn: https://www.linkedin.com/company/eha/

Email us: [email protected]

Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe 

Join us for an interview with Prof Ivo Touw, who has received the prestigious EHA David Grimwade Award for his contributions to the field of hematology research. Prof Touw and his research group focus on molecular signaling in leukemia predisposition syndromes, such as severe congenital neutropenia (SCN). They have described the dysfunction of the membrane receptor for the growth factor G-CSF and its role in SCN and malignant transformation to acute myeloid leukemia. In this interview prof.

Touw talks about his career path and choices that he has made along the way. He tells about his early fascination with the growth factors and how leukemia cells respond to them, which has driven his scientific career ever since. The simple questions such as “how can the growth factor in some cells only induce a proliferative response and in others both proliferation and differentiation?” or “why does one patient respond to G-SCF therapy and another does not?” triggered the discoveries of the complex underlying biological mechanisms.

If you want to hear about the stepwise discoveries of the roles of G-SCF mutants, RUNX gene and inflammatory stress and using novel technologies such as induced pluripotent stem (iPS) technology, CRISPR technology and computational biology, tune in to this episode with Prof Ivo Touw. He will also share his thoughts on the new avenues for thinking about therapy for SCN, such as repairing stem cells for autologous transplant or repurposing already available drugs.  

Host: Isabel Olivera-Martinez, PhD, Medical Writer

Guest: Prof Ivo Touw

What did you think of this podcast? Share your opinions with us in this short feedback survey.

Provide Feedback

Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.

https://ehaedu.org/Campus

Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.

Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/

Facebook: https://e-h-a.link/facebook

LinkedIn: https://www.linkedin.com/company/eha/

Email us: [email protected]

Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe 

Join us for an insightful interview with Professor Saskia Middeldorp from Radboud University Medical Center in Nijmegen, The Netherlands, as she and our host Dr. Isabel Olivera-Martinez, discuss the medical and ethical challenges of conducting randomized clinical trials to prevent venous thromboembolism (VTE) during pregnancy. 

VTE is a leading cause of maternal morbidity and mortality, and poses significant risks to pregnant women. Together, explore the relevance of prophylactic treatments like low molecular weight heparin, and the ethical and financial complexities of conducting trials in this population. Learn about the ALIFE2 trial results, that assessed whether LMWH heparin should be used in women with recurrent miscarriage and inherited thrombophilia; well as the latest research and guidelines aimed at improving care for pregnant women at risk of VTE. 

Host: Isabel Olivera-Martinez, PhD, Medical Writer

Guest: Prof Saskia Middeldorp

If you liked this podcast and would like to explore related content, you can check out our clinical case about Thrombosis and Hemostasis on the EHA Campus.

What did you think of this podcast? Share your opinions with us in this short feedback survey.

Provide Feedback

Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.

https://ehaedu.org/Campus

Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.

Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/

Facebook: https://e-h-a.link/facebook

LinkedIn: https://www.linkedin.com/company/eha/

Email us: [email protected]

Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe